Panoply™ Human PRPF40B Knockdown Stable Cell Line

Cervical squamous cell carcinoma and cervical adenocarcinoma (CESC) continue to pose a significant threat to women's health, especially in locally advanced patients. Therefore, there is an urgent need to develop more effective prognostic biomarkers. Here, researchers constructed and validated a robust RNA-binding protein (RBP)-related biomarker using a series of bioinformatics methods and explored the biological functions of key RBPs through in vitro experiments. The results showed that the successfully constructed biomarker containing 10 RBPs can serve as an independent prognostic biomarker for CESC patients, exhibiting the highest sensitivity and specificity in prognostic prediction compared to other clinicopathological parameters. Functional enrichment analysis indicated that this risk profile is primarily involved in immune-related and cancer-related pathways, with significantly higher levels of immune cell infiltration and immune checkpoint expression in low-risk patients compared to high-risk patients. Notably, these 10 RNA-binding protein (RBP) profiles can serve as novel biomarkers for immunotherapy and chemotherapy responses. Furthermore, PRPF40B was selected as a key RBP, with significantly elevated transcription and translation levels in cervical epithelial carcinoma (CESC) tissues, as well as in HeLa and Siha cells. In vitro experiments showed that knocking down PRPF40B inhibited the proliferation, migration, and invasion of HeLa and Siha cells. In summary, these findings provide a novel strategy for predicting the prognosis of cervical epithelial cancer patients, and hold promise for improving their clinical outcomes.

To assess the biological function of PRPF40B, researchers conducted experimental validation. Western blot results showed that PRPF40B expression was successfully knocked down in HeLa and Siha cell lines (Figure 1A, G). CCK-8 assays showed that the proliferation of PRPF40B knockdown HeLa and Siha cells was significantly inhibited (Figure 1B, H). Scratch assays showed that PRPF40B knockdown significantly inhibited the growth of HeLa and Siha cells (Figure 1C, D, I, J). Consistent with these results, Transwell assays showed that the migration and invasion abilities of PRPF40B knockdown cells were significantly inhibited (Figure 1E, F, K, L). These results indicate that PRPF40B plays an oncogene role in CESCs, consistent with its prognostic effects.

Figure 1. Investigate the biological function of PRPF40B in CESC cell lines. (Chen X, et al., 2024)